Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Oleg E. Akilov"'
CD5+ Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Presenting as an Asymptomatic Nodule
Publikováno v:
Hematology Reports, Vol 15, Iss 3, Pp 513-517 (2023)
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), is a rare and aggressive variant of primary cutaneous lymphoma that typically expresses B cells as well as MUM1/IRF4, BCL2, and FOXP1, whereas BCL6 may be present or undetectable
Externí odkaz:
https://doaj.org/article/b3f0ac2ddb684167a6e7e18922615e4b
Publikováno v:
JAAD Case Reports, Vol 30, Iss , Pp 38-40 (2022)
Externí odkaz:
https://doaj.org/article/89ccdddca20b44e5b333ee5679f0d48c
Autor:
Oleg E. Akilov
Publikováno v:
Cells, Vol 12, Iss 18, p 2321 (2023)
Extracorporeal photopheresis (ECP) is an FDA-approved immunotherapy for cutaneous T-cell lymphoma, which can provide a complete response in some patients. However, it is still being determined who will respond well, and predictive biomarkers are urge
Externí odkaz:
https://doaj.org/article/42ca3ee44b454996881d98bf19fc123f
Autor:
Ishan Asokan, MD, MSc, Sanminder Singh, MD, John Moesch, DO, Jonhan Ho, MD, Oleg E. Akilov, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 20, Iss , Pp 44-46 (2022)
Externí odkaz:
https://doaj.org/article/4a3e54b1f4214aed95bb24542a181548
Autor:
Amy Xiao, Oleg E. Akilov
Publikováno v:
Cells, Vol 11, Iss 22, p 3591 (2022)
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fung
Externí odkaz:
https://doaj.org/article/e3638040bc67479c9cad8ffb9e2a7d01
Autor:
Iris Amitay-Laish, Emmanuella Guenova, Pablo L. Ortiz-Romero, Cristina Vico-Alonso, Sima Rozati, Larisa J. Geskin, Vasiliki Nikolaou, Evangelia Papadavid, Aviv Barzilai, Lev Pavlovsky, Elena Didkovsky, Hadas Prag Naveh, Oleg E. Akilov, Emmilia Hodak
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 16, p adv00277 (2020)
Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with
Externí odkaz:
https://doaj.org/article/1b631c873653447d9d0fee2e7444604b
Autor:
Raman Preet Kaur Gill, Jennifer Gantchev, Amelia Martínez Villarreal, Brandon Ramchatesingh, Elena Netchiporouk, Oleg E. Akilov, Niels Ødum, Robert Gniadecki, Sergei B. Koralov, Ivan V. Litvinov
Publikováno v:
Cells, Vol 11, Iss 4, p 593 (2022)
Cutaneous T cell lymphoma (CTCL) is a spectrum of lymphoproliferative disorders caused by the infiltration of malignant T cells into the skin. The most common variants of CTCL include mycosis fungoides (MF), Sézary syndrome (SS) and CD30+ Lymphoprol
Externí odkaz:
https://doaj.org/article/db3fc904cfe9480293ac250c190b122f
Publikováno v:
Journal of Dermatological Treatment, Vol 29, Iss 3, Pp 272-276 (2018)
Background: Phototherapy has been a mainstay in the treatment of mycosis fungoides (MF). However, the recent findings of UV-induced p53 mutations in advanced MF suggest that phototherapy may contribute to disease progression. Objective: The objective
Externí odkaz:
https://doaj.org/article/4008b61de53b47748b589d7cace18bfa
Autor:
Tony T. Jiang, Oleg Kruglov, Gloria H. Y. Lin, Angela Minic, Kimberly Jordan, Robert A. Uger, Mark Wong, Yaping Shou, Oleg E. Akilov
Publikováno v:
Cancers, Vol 13, Iss 23, p 5982 (2021)
Cancer progression in mycosis fungoides, the most common form of cutaneous T-cell lymphoma, occurs in a predictable, sequential pattern that starts from patches and that evolves to plaques and later to tumors. Therefore, unlocking the relationship be
Externí odkaz:
https://doaj.org/article/61f08444e04c4bbc9a7734cd61a59dba
Autor:
David M. Lemchak, Oleg E. Akilov
Publikováno v:
Hematology Reports, Vol 8, Iss 4 (2016)
Romidepsin belongs to a class of medications called histone deacetylase inhibitors and is currently approved for treatment of cutaneous and peripheral T-cell lymphomas. Romidepsin was previously investigated for the treatment of chronic lymphocytic l
Externí odkaz:
https://doaj.org/article/838b235229f14d858d0fe2caf061a54c